PBM
KLRS

Propel Bio Management’s Kalaris Therapeutics KLRS Stock Holding History

Propel Bio Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-295,771
Closed -$1.72M – 39
2026
Q1 		$1.72M Buy
295,771
+253,718
+603% +$2.25M 1.08% 28
2025
Q4 		$355K Buy
+42,053
New +$269K 0.3% 20

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Propel Bio Management's KLRS Position: Q2 2026 in Review

Propel Bio Management sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 295,771 shares — an estimated $1.72M sold.

Propel Bio Management first reported a position in KLRS in Q4 2025 and held it in 2 quarters. The position peaked at $1.72M in Q1 2026. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Propel Bio Management reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 295,771 Kalaris Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Propel Bio Management first reported a position in Kalaris Therapeutics in Q4 2025 and held it in 2 quarters.
  • Propel Bio Management's Kalaris Therapeutics position peaked at $1.72M in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.